In a report of 47 patients who developed LA while on metformin, 43 had one or more risk factors including congestive heart failure (CHF) and renal insufficiency. There are many reports in the literature about continued use of metformin in the presence of contraindications. Use of metformin in the presence of contraindications Out of those, five patients had sepsis and signs of end-organ damage, suggesting that LA most frequently occurs in acutely worsening clinical scenarios. In a nested case–control analysis that included 50 048 patients, six patients were identified with active use of metformin and LA. The putative risk factors for LA described in the literature include old age, decreased cardiac output, respiratory failure or hypoxic conditions, ethanol intoxication, fasting and decreased hepatic function. Since DM2 is a risk factor, it is thought that many such cases may have been just from DM2. Many reported cases of LA had multiple risk factors besides renal failure. reported that after starting to use metformin, rates of LA in the USA were no different from prior to the approval of metformin. Many reported cases of metformin-associated LA (MALA) did not measure metformin levels, whereas in others levels were not high, suggesting ‘metformin coincident lactic acidosis’. Although the fear of LA remains, no absolute definitive causal relationship has been proven beyond doubt. Metformin is chemically similar to phenformin, but has a different mechanism of action. With all the mounting evidence, the FDA is finally requiring labeling changes regarding recommendations, to allow the use of metformin in patients with much reduced kidney function. It will simplify the use of diabetes mellitus type 2 management with lower incidences of hypoglycemia. More widespread use of metformin will further help with health care costs, as well as obesity. Metformin’s costs are lower, and in many underdeveloped countries this is the only medicine available for poor patients. These guidelines also suggest moving away from just looking at serum creatinine to create a cut-off. Current guidelines, though somewhat vague regarding dosages, clearly pave the way for spreading the use of metformin in patients with lower glomerular filtration rates. Since many diabetic patients have chronic kidney disease, its use is often curtailed by practitioners due to fear of lactic acidosis and the US Food and Drug Administration (FDA) warnings that, until recently, had been in place for decades. It is the only such medicine that has shown a reduction of cardiovascular mortality in diabetes mellitus type 2. Metformin is one of the oldest and most widely prescribed antidiabetic medicines worldwide.
0 kommentar(er)
